Trial Profile
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms SUSTRENIM
- 12 Dec 2023 Results assessing the percentage of patients achieving the eligibility to treatment discontinuation, defined as a MR4 maintained in 4 consecutive MRD analysis within the fourth year of therapy, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 17 Jun 2022 Results presented at the 27th Congress of the European Haematology Association
- 04 Jan 2022 Status changed from recruiting to active, no longer recruiting.